RQ Bio chief executive Hugo Fry joins Katie to talk about its deal with AstraZeneca PLC (LSE:AZN) (AZ) and its official launch.
The biotech company discussed the $157mln licensing deal giving AZ the right to develop and sell six antibodies, none of which have been tested in humans so far.